Home » Topics » BioWorld Science

BioWorld Science
RSS

Silverback Therapeutics synthesizes TGFR-1 inhibitors and antibody-drug conjugates

May 6, 2022

Enliven Therapeutics describes new Bcr-Abl kinase inhibitors

May 6, 2022

BCY-6033: EphA2-targeting BTC with efficacy in NSCLC PDX models

May 6, 2022

Researchers discover HDAC1 as the cause of immune abnormalities in autistic mouse models

May 5, 2022

DGKk gene therapy rescues brain lipid profiles and long-term behavior in fragile X syndrome mice

May 5, 2022

ALTA-2530 shows preclinical efficacy as potential treatment of bronchiolitis obliterans syndrome

May 5, 2022

FDA awards orphan drug designation to AB-001 for pancreatic cancer and AML

May 5, 2022

CDK7 inhibitor GTAEXS-617 shows potent antitumor activity in vivo

May 5, 2022

TRAIL protein levels may predict response to acamprosate in alcohol use disorder

May 5, 2022

M1 mAChR antagonism attenuates opioid drug seeking behaviors in rat

May 5, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....